Navigation Links
Sound Pharmaceuticals Files Second IND with the FDA for the Prevention of Chemotherapy Induced Hearing Loss in Advanced Stage Cancer
Date:7/23/2008

SEATTLE, July 23 /PRNewswire/ -- Sound Pharmaceuticals (SPI) has filed an Investigational New Drug Application with the FDA for the clinical testing of a proprietary formulation of ebselen for the prevention of chemotherapy induced hearing loss or ototoxicity. The oral capsule containing ebselen, SPI-3005, will be tested in advanced stage lung cancer and head and neck cancer patients receiving platinum based chemotherapy. This marks the second development program for SPI to enter clinical testing for a hearing loss indication. Last year, SPI-1005, an oral capsule containing ebselen entered Phase II testing with the US Navy for the prevention and treatment of noise induced hearing loss.

Currently there are no FDA approved drugs for the prevention and treatment of drug induced hearing loss or ototoxicity. SPI hopes to address this unmet medical need with its first in class first in indication drug. Several different research groups have shown that chemotherapy treatment reduces glutathione peroxidase (GPx) activity in the mammalian inner ear resulting in hearing loss, tinnitus, vertigo and dizziness. GPx is the dominant catalytic antioxidant enzyme within the inner ear, and a loss of its activity results in irreparable damage to hair cells, neurons and non-sensory tissues that are critical for hearing and balance. "A dose limiting side effect of platinum based chemotherapies are their devastating ototoxicity and neurotoxicity, and SPI-3005 is designed to attenuate these side effects without inhibiting the therapeutic efficacy of platinum or taxane based chemotherapies," said VP Eric Lynch, PhD.

"Otoprotectants such as SPI-3005 have the potential to reduce and/or alleviate chemotherapy-induced ototoxicity, and clinical studies should be pursued," said Stephen Fausti, PhD, and Director of the National Center for Rehabilitative Auditory Research (NCRAR) at the Portland VA, Professor of Otolaryngology and Neurology at Oregon Health Sciences University.

Sound Pharmaceuticals, Inc., is a privately held biopharmaceutical company with a focus on developing the first drugs for hearing loss and brain injury. For more information please contact Jonathan Kil, MD, President and CEO, 206-634-2559 or http://www.soundpharma.com.


'/>"/>
SOURCE Sound Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Actress and New Mom Keri Russell Joins PKIDs to launch Silence the Sounds of Pertussis Campaign
2. Video: Actress and New Mom Keri Russell Joins PKIDs to Launch Silence the Sounds of Pertussis Campaign
3. Adding Breast Ultrasound Screening to Mammography Reveals Cancers not Seen on Mammography Alone in Women at Increased Risk for Breast Cancer
4. Applisonix Announces Breakthrough in Ultrasound Technology for Hair Removal - Average Hair Reduction of 38% Following Initial Treatment
5. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
6. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
7. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
8. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
9. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
10. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
11. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2016)... N.J. , May 24, 2016 ... oncology drug development company, today provided an update ... dose escalating clinical trial combining GEN-1, the Company,s ... the treatment of newly-diagnosed patients with advanced ovarian ... interval debulking surgery.  GEN-1 is an IL-12 DNA ...
(Date:5/24/2016)... May 24, 2016 Los ... terapia del mundo, introduce catéteres para la intervención ... OrbusNeich, una compañía global especializada en el suministro ... expandido su cartera incluyendo productos para tratar la ... Scoreflex™ PTA son los dispositivos de primera entrada ...
(Date:5/24/2016)... Dutch surgeons have launched a ground-breaking medical app to help doctors ... a global scale. Medical professionals from Europe , ... the US have already signed up for the app, which combines ... environment. Education  "Imagine a doctor for Medicines ... at Harvard to treat a bomb victim via live streaming - ...
Breaking Medicine Technology:
(Date:5/26/2016)... ... May 26, 2016 , ... A health conscious snack ... The Dough Bar, has ignited an undeniable buzz in the protein product community ... not just any doughnut.  These doughnuts are packed with 11 grams of protein and ...
(Date:5/26/2016)... Boston, MA (PRWEB) , ... May 26, 2016 ... ... working to enhance surgical safety efforts for several years, and the efforts have ... significantly decreased. These efforts include new standards of care to enhance perioperative patient ...
(Date:5/26/2016)... ... May 26, 2016 , ... ... seeking nominations to serve on its Accreditation and Standards Committees and support ... quality-benchmarking activities incorporate key process and outcome measures, with the ultimate mission ...
(Date:5/26/2016)... ... May 26, 2016 , ... Dalton Pharma Services, ... has successfully completed another Health Canada inspection and has received a compliant rating ... resulted from a Good Manufacturing Practices (GMP) inspection conducted at Dalton’s facility during ...
(Date:5/26/2016)... ... May 26, 2016 , ... HealthPostures, ergonomics designer and maker ... furniture that may support women during pregnancy. Potential benefits of using the Stance Angle ... and comfort and healthier levels of sitting and standing. , Need for the ergonomics ...
Breaking Medicine News(10 mins):